Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Morley, Samantha ^a,b,c   You, Sungyong ^a   Pollan, Sara ^a   Choi, Jiyoung ^b   Zhou, Bo ^a   Hager, Martin H ^b,c   Steadman, Kenneth ^a   Spinelli, Cristiana ^a   Rajendran, Kavitha ^d   Gertych, Arkadiusz ^a   Kim, Jayoung ^a,b,c   Adam, Rosalyn M ^b,c   Yang, Wei ^a   Krishnan, Ramaswamy ^d   Knudsen, Beatrice S ^a   Di Vizio, Dolores ^a,b,c   Freeman, Michael R ^a,b,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAPH3 PROTEIN, HUMAN; EPOTHILONE B; EPOTHILONE DERIVATIVE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAXOID;

BREAST NEOPLASMS; FEMALE; GENE SILENCING; GENETICS; HUMAN; MALE; MICROTUBULE; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; EPOTHILONES; FEMALE; GENE SILENCING; HUMANS; MALE; MICROTUBULES; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84937597591     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12136     Document Type: Article

References (60)

1. Sahai, E. & Marshall, C. J. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol. 5, 711-719 (2003).
2. Wolf, K. et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol. 160, 267-277 (2003).
3. Sanz-Moreno, V. et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell. 135, 510-523 (2008).
4. Tozluoglu, M. et al. Matrix geometry determines optimal cancer cell migration strategy and modulates response to interventions. Nat Cell Biol. 15, 751-762 (2013).
5. Hager, M. H. et al. DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Mol Med. 4, 743-760 (2012).
6. Kim, J. et al. Enhanced shedding of extracellular vesicles from amoeboid prostate cancer cells: potential effects on the tumor microenvironment. Cancer Biol Ther. 15, 409-418 (2014).
7. Soon, L., Braet, F. & Condeelis, J. Moving in the right direction-nanoimaging in cancer cell motility and metastasis. Microsc Res Tech. 70, 252-257 (2007).
8. Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J Clin Invest. 119, 1420-1428 (2009).
9. Friedl, P. & Wolf, K. Plasticity of cell migration: a multiscale tuning model. J Cell Biol. 188, 11-19 (2009).
10. Renkawitz, J. et al. Adaptive force transmission in amoeboid cell migration. Nat Cell Biol. 11, 1438-1443 (2009).
11. Wang, W. et al. Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res. 62, 6278-6288 (2002).
12. Wyckoff, J. B., Pinner, S. E., Gschmeissner, S., Condeelis, J. S. & Sahai, E. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol. 16, 1515-1523 (2006).
13. Orgaz, J. L. et al. Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. Nat Commun. 5, 4255 (2014).
14. Baldassarre, G. et al. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell. 7, 51-63 (2005).
15. Belletti, B. et al. Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell. 19, 2003-2013 (2008).
16. Belletti, B. et al. p27kip1 controls cell morphology and motility by regulating microtubule-dependent lipid raft recycling. Mol Cell Biol. 30, 2229-2240 (2010).
17. Berton, S. et al. The tumor suppressor functions of p27(kip1) include control of the mesenchymal/amoeboid transition. Mol Cell Biol. 29, 5031-5045 (2009).
18. Goode, B. L. & Eck, M. J. Mechanism and function of formins in the control of actin assembly. Annu Rev Biochem. 76, 593-627 (2007).
19. Di Vizio, D. et al. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 69, 5601-5609 (2009).
20. Di Vizio, D. et al. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol. 181, 1573-1584 (2012).
21. Schulze, E., Asai, D. J., Bulinski, J. C. & Kirschner, M. Posttranslational modification and microtubule stability. J Cell Biol. 105, 2167-2177 (1987).
22. Schulze, E. & Kirschner, M. Dynamic and stable populations of microtubules in cells. J Cell Biol. 104, 277-288 (1987).
23. Schiff, P. B. & Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 77, 1561-1565 (1980).
24. Rogers, G. C., Rogers, S. L. & Sharp, D. J. Spindle microtubules in flux. J Cell Sci. 118, 1105-1116 (2005).
25. Kovar, J. et al. Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells. Anticancer Res. 29, 2951-2960 (2009).
26. Mitchison, T. J. The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell. 23, 1-6 (2012).
27. Holmes, F. A. et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 83, 1797-1805 (1991).
28. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351, 1502-1512 (2004).
29. Esserman, L. J. et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 132, 1049-1062 (2012).
30. Esserman, L. J. et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 30, 3242-3249 (2012).
31. Galletti, G. et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun. 5, 5548 (2014).
32. Thuerigen, O. et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol. 24, 1839-1845 (2006).
33. Hess, K. R. et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 24, 4236-4244 (2006).
34. Tabchy, A. et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 16, 5351-5361 (2010).
35. Hatzis, C. et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. Jama. 305, 1873-1881 (2011).
36. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 18, 11-22 (2010).
37. Freije, W. A. et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 64, 6503-6510 (2004).
38. Delphin, C. et al. MAP6-F is a temperature sensor that directly binds to and protects microtubules from cold-induced depolymerization. J Biol Chem. 287, 35127-35138 (2012).
39. Krishnan, R. et al. Reinforcement versus fluidization in cytoskeletal mechanoresponsiveness. PLoS One. 4, e5486 (2009).
40. Stamenovic, D., Mijailovich, S. M., Tolic-Norrelykke, I. M., Chen, J. & Wang, N. Cell prestress. II. Contribution of microtubules. Am J Physiol Cell Physiol. 282, C617-624 (2002).
41. Rape, A., Guo, W. H. & Wang, Y. L. Microtubule depolymerization induces traction force increase through two distinct pathways. J Cell Sci. 124, 4233-4240 (2011).
42. Gertych, A. et al. Automated quantification of DNA demethylation effects in cells via 3D mapping of nuclear signatures and population homogeneity assessment. Cytometry A. 75, 569-583 (2009).
43. Takemura, R. et al. Increased microtubule stability and alpha tubulin acetylation in cells transfected with microtubule-associated proteins MAP1B, MAP2 or tau. J Cell Sci. 103 (Pt 4), 953-964 (1992).
44. Darshan, M. S. et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71, 6019-6029 (2011).
45. Martin, S. K., Banuelos, C. A., Sadar, M. D. & Kyprianou, N. N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Mol Oncol. doi: 10.1016/j.molonc.2014.10.014. (2014).
46. Zhu, M. L. et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70, 7992-8002 (2010).
47. Shankavaram, U. T. et al. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics. 10, 277 (2009).
48. Puhr, M. et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol. 181, 2188-2201 (2012).
49. Febbo, P. G. et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 11, 5233-5240 (2005).
50. Smith, L. A., Aranda-Espinoza, H., Haun, J. B., Dembo, M. & Hammer, D. A. Neutrophil traction stresses are concentrated in the uropod during migration. Biophys J. 92, L58-60 (2007).
51. Meili, R., Alonso-Latorre, B., del Alamo, J. C., Firtel, R. A. & Lasheras, J. C. Myosin II is essential for the spatiotemporal organization of traction forces during cell motility. Mol Biol Cell. 21, 405-417 (2010).
52. Johansson, I., Ringner, M. & Hedenfalk, I. The Landscape of Candidate Driver Genes Differs between Male and Female Breast Cancer. PLoS One. 8, e78299 (2013).
53. Chen, C. et al. Fluidization and resolidification of the human bladder smooth muscle cell in response to transient stretch. PLoS One. 5, e12035 (2010).
54. Butler, J. P., Tolic-Norrelykke, I. M., Fabry, B. & Fredberg, J. J. Traction fields, moments, and strain energy that cells exert on their surroundings. Am J Physiol Cell Physiol. 282, C595-605 (2002).
55. Prager-Khoutorsky, M. et al. Fibroblast polarization is a matrix-rigidity-dependent process controlled by focal adhesion mechanosensing. Nat Cell Biol. 13, 1457-1465 (2013).
56. Yang, W. et al. Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. J Proteome Res. 9, 3073-3082 (2010).
57. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 26, 1367-1372 (2008).
58. Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res. 10, 1794-1805 (2011).
59. Vizcaino, J. A. et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol. 32, 223-226 (2014).
60. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4, 44-57 (2009).